The global anti-inflammatory drugs market size was valued US$ XX billion in 2022 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).
Anti-inflammatory drugs are the drugs that are used to treat conditions like asthma, arthritis, chronic obstructive pulmonary disease (COPD), and other diseases. Immune-Mediated Inflammatory diseases represent a global threat in terms of quality of life, morbidity, and mortality that leads to an increased opportunity to develop new treatments.
The global anti-inflammatory Drugs Market growth is driven by the increasing autoimmune and respiratory conditions, new drugs in the pipeline, and increasing adoption of anti-inflammatory drugs.
The increasing prevalence of these diseases is the major factor propelling the market upwards
The increasing prevalence of these diseases is the major factor propelling the market upwards. The demand for anti-inflammatory drugs has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted, effective, and with lesser side effects as compared to conventional drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives are expected to drive the market during the forecast period.
For instance, according to the findings of the Rheumatoid Arthritis Support Network (RASN), more than 1.3 million people in the U.S. suffer from rheumatoid arthritis. On a global scale, almost 1% of the population is diagnosed with this disorder. As the treatment and cure for this autoimmune disease are still unknown, the only possible way of easing pain is through the intake of anti-inflammatory drugs. As a result, the global market for these drugs is slated to witness considerable growth.
Increasing sedentary lifestyle and deteriorating air quality
The anti-inflammatory drugs help suppress the inadvertent alarm, the immune system triggers against body cells, which causes inflammation in the various body part. With the increasingly sedentary lifestyle and deteriorating air quality in many parts of the world, the prevalence of arthritis and respiratory-related diseases are on the rise. Hence, there has been an increase in the anti-inflammatory drugs market in the past decade, and the trend seems to only increase at a much healthier rate.
Risks associated with use is likely to hinder the market growth
However, the side effects of using anti-inflammatory drugs such as dizziness, allergic reactions, stomach pain, stomach ulcers, and others may pose a major threat to the market. This, coupled with the risk of gastrointestinal bleeding and other complications may hinder the market in the forecast period.
COVID-19 Impact Analysis
The impact of the COVID-19 pandemic is expected to remain positive for the anti-inflammatory drugs market, owing to the inflammation caused by COVID. SARS-CoV-2 is a beta coronavirus causing severe anti-inflammatory pneumonia, as COVID-19 can cause severe inflammation in patients diagnosed with it. According to reports, cytokine storm is strongly responsible for death in such patients. Some of the consequences of severe inflammation and cytokine storms include acute respiratory distress syndrome, acute lung injury, and multiple organ dysfunction syndromes, which lead to an increase in the research and the development of anti-inflammatory drugs for the treatment of inflammation caused by COVID-19. For instance, many clinical trials are currently underway to alleviate this destructive inflammation. One of them is NLRP3 inflammasome, which targets multiple mechanisms associated with COVID-19 excessive inflammation. Thus, such factors have positively impacted the market growth during the pandemic.
The arthritis segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Arthritis is the inflammation in the joints. There are different types of arthritis, osteoarthritis and rheumatoid arthritis being most common among them. Arthritis is found to be more prevalent in the geriatric population, but there have been some documented cases of arthritis in children as well. Osteoarthritis is caused due to the breakdown of protective cartilage, causing pain and movement of joints difficult. Non-steroidal Anti-Inflammatory Drugs (NSAIDs) like diclofenac, ibuprofen, and naproxen have been proven to be very effective in suppressing the pain from Osteoarthritis but may cause side effects like stomach upset, cardiovascular problems, bleeding problems, and liver and kidney damage.
Osteoarthritis breaks the cartilage of the joints which is a slippery tissue covering the ends of bones in a joint. The geriatric population and over-weighted individuals are at higher risks of osteoarthritis. The growing geriatric population, rising prevalence of osteoarthritis, and increasing per capita healthcare expenditure will drive the segment growth. For instance, in 2015, according to the National Institutes of Health, the American geriatric population is expected to nearly double from 48 million in 2015 to 88 million by 2050. Moreover, according to the Centers for Disease Control and Prevention about 78 million (26%) U.S. adults aged 18 years or more are estimated to have doctor-diagnosed arthritis, by 2020. This factor is driving the growth of the segment in the forecast period.
Rheumatoid arthritis is associated with autoimmune that causes inflammation in joints of the body further the disease affects the muscle, connective tissues, joints, fibrous tissue, and tendons. Rheumatoid arthritis has a major negative effect on the ability to perform health-related quality of life daily activities, including work and household tasks, and it increases mortality. Rheumatoid arthritis strikes in the between the ages of 20 and 40, most productive years of adulthood, and is a chronic immobilizing condition often causing deformity and pain. The prevalence of rheumatoid arthritis differs between 0.3% and 1% and is more common in developed countries mostly in women.
Rheumatoid arthritis causes disability, premature death, and lowers the quality of life in the developing and industrialized world. Rheumatoid arthritis is a universal inflammatory disease that establishes itself in various joints in the body. This inflammation typically transforms the organs of the body, but can also affect the lining of the joints. This inflamed joint lining tends to disintegrate the bone and joint deformity and sometimes causes cartilage. The prevalence of rheumatoid arthritis is driving the growth of the market in the forecast period.
The nonsteroidal anti-inflammatory drugs (NSAIDS), are expected to dominate the anti-inflammatory drugs market during the forecast period
Nonsteroidal anti-inflammatory agents (NSAIDs) are a group of medicines that relieve pain and fever and reduce inflammation. There are nearly two dozen different NSAIDs available, but they all work in the same way, and that is by blocking a specific group of enzymes called cyclo-oxygenase enzymes, often abbreviated to COX enzymes. These enzymes are responsible for the production of prostaglandins. Prostaglandins are a group of compounds with hormone-like effects that control many different processes such as inflammation, blood flow, and the formation of blood clots.
Some individuals are allergic to NSAIDs and may develop shortness of breath when an NSAID is taken. People with asthma are at a higher risk of experiencing a serious allergic reaction to NSAIDs. Individuals with a serious allergy to one NSAID are likely to experience a similar reaction to a different NSAID.
North America region holds the largest market share global anti-inflammatory drugs market
North America region is dominating the global anti-inflammatory drugs market accounted for the largest market share in 2020, owing to the factors such as the established healthcare sector with a large number of renowned players, high investment & demand for more effective and safer drugs, etc. Moreover, the high income per capita, rise in inpatient visits to physicians, research advancements due to high funding are some of the factors that are driving the growth of the market in the region.
The anti-inflammatory drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc, AstraZeneca, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb, F-Hoffmann-La-Roche, Eli Lilly, and Sanofi among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anti-inflammatory drugs market globally.
Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
Product Portfolio: The Company’s portfolio is comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology, and neuroscience areas.
Key Development: On Sept. 23, 2016, the U.S. Food and Drug Administration (FDA) has approved AMJEVITA (adalimumab-atto) across all eligible indications of the reference product, Humira (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe chronic plaque psoriasis, adult moderate-to-severe Crohn's disease, and moderate-to-severe ulcerative colitis. AMJEVITA is Amgen's first biosimilar to receive regulatory approval.
Get your free sample proposal with a single click!